This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1994 Feb;12(2):233-6.

doi: 10.1200/JCO.1994.12.2.233.

Paclitaxel: what schedule? What dose?

PMID: 7509379
DOI: 10.1200/JCO.1994.12.2.233

Editorial

Paclitaxel: what schedule? What dose?

S G Arbuck. J Clin Oncol. 1994 Feb.

. 1994 Feb;12(2):233-6.

doi: 10.1200/JCO.1994.12.2.233.

Author

PMID: 7509379
DOI: 10.1200/JCO.1994.12.2.233

No abstract available

PubMed Disclaimer

Comment on

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D. Schiller JH, et al. J Clin Oncol. 1994 Feb;12(2):241-8. doi: 10.1200/JCO.1994.12.2.241. J Clin Oncol. 1994. PMID: 7509380 Clinical Trial.

Similar articles

Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ, Meyers FJ, Houston J, Lauder I. Edelman MJ, et al. Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-68-S15-71. Semin Oncol. 1997. PMID: 9346226 Clinical Trial.
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Hesketh PJ, McCoy J, Dunphy FR 2nd, Bearden JD 3rd, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR. Hesketh PJ, et al. J Thorac Oncol. 2006 Nov;1(9):991-5. J Thorac Oncol. 2006. PMID: 17409984 Clinical Trial.
Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer.
Belani CP, Aisner J, Hiponia D, Engstrom C. Belani CP, et al. Semin Oncol. 1995 Aug;22(4 Suppl 9):7-12. Semin Oncol. 1995. PMID: 7544028 Clinical Trial.
[Role of G-CSF for breast cancer chemotherapy].
Suzuki Y, Saito Y, Tokuda Y. Suzuki Y, et al. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:572-4. Nihon Rinsho. 2007. PMID: 17679213 Review. Japanese. No abstract available.
Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer.
Tolcher AW. Tolcher AW. Semin Oncol. 1996 Feb;23(1 Suppl 1):37-43. Semin Oncol. 1996. PMID: 8629035 Review.

See all similar articles

Cited by

Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
Einzig AI, Wiernik PH, Wadler S, Kaplan J, Benson LT, Tentoramano L, Tan V. Einzig AI, et al. Invest New Drugs. 1998;16(1):29-36. doi: 10.1023/a:1006004809169. Invest New Drugs. 1998. PMID: 9740541 Clinical Trial.
Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
Kano Y, Akutsu M, Tsunoda S, Ando J, Matsui J, Suzuki K, Ikeda T, Inoue Y, Adachi K. Kano Y, et al. Br J Cancer. 1996 Sep;74(5):704-10. doi: 10.1038/bjc.1996.425. Br J Cancer. 1996. PMID: 8795571 Free PMC article.
Clinical pharmacokinetics of paclitaxel.
Sonnichsen DS, Relling MV. Sonnichsen DS, et al. Clin Pharmacokinet. 1994 Oct;27(4):256-69. doi: 10.2165/00003088-199427040-00002. Clin Pharmacokinet. 1994. PMID: 7834963 Review.
Breast cancer therapies in development. A review of their pharmacology and clinical potential.
de Valeriola D, Awada A, Roy JA, Di Leo A, Biganzoli L, Piccart M. de Valeriola D, et al. Drugs. 1997 Sep;54(3):385-413. doi: 10.2165/00003495-199754030-00003. Drugs. 1997. PMID: 9279502 Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.